# Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab

> **NCT02029326** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02029326
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-08-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029326, "Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02029326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*